Daniel Morillo, MD, discusses the mechanism of action of golcadomide as a potential treatment for relapsed/refractory follicular lymphoma.
Daniel Morillo, MD
Advertisement
Daniel Morillo, MD, is a consultant hematologist in the Lymphoma Unit and a clinical investigator at the Early Phase Clinical Trials Unit (START Madrid–FJD) at Hospital Universitario Fundación Jiménez Díaz.
Articles by Daniel Morillo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
4
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
5